Key result
SARS-CoV-2 infection was not associated with altered serum levels of ACE2, angiotensin II, or aldosterone compared to symptomatic SARS-CoV-2 negative patients.
Why the study?
The role of the renin-angiotensin-aldosterone system (RAAS) in COVID-19 is controversially discussed, and RAAS activity may affect susceptibility to SARS-CoV-2 infection and patient outcomes.
Does SARS-CoV-2 infection alter serum levels of ACE2, angiotensin II, and aldosterone compared to patients with similar symptoms without COVID-19?
Observational (n=85)
No
Does SARS-CoV-2 infection alter serum levels of ACE2, angiotensin II, and aldosterone compared to patients with similar symptoms without COVID-19?
SARS-CoV-2 infection does not appear to significantly alter systemic RAAS activity, including ACE2, angiotensin II, and aldosterone levels, at the time of emergency department presentation.
Answers are grounded in this paper and cite their sources.
No RAAS marker differences at ED presentation in this cohort; leaves open effects in severe, hospitalized, or post-acute COVID-19.
BACKGROUND: The role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) and activity of the RAAS may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19. METHODS: In this prospective single-center study, we determined the serum levels of ACE2, angiotensin II, and aldosterone in patients with COVID-19 compared with control patients presenting with similar symptoms in the emergency unit. RESULTS: We analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms, and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups. CONCLUSIONS: In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19. CLINICAL TRIALS REGISTRATION: Trial Number DRKS00021206.
No takes yet. Share an insight, caveat, or question.
Rieder et al. (2020) conducted an observational in COVID-19 (n=85). SARS-CoV-2 infection vs. SARS-CoV-2 negative patients with similar symptoms was evaluated on Serum levels of ACE2, angiotensin II, and aldosterone. SARS-CoV-2 infection was not associated with altered serum levels of ACE2, angiotensin II, or aldosterone compared to symptomatic SARS-CoV-2 negative patients.
Synapse has enriched 10 related papers. Consider them for comparative context: